Pasithea Therapeutics
KTTA
10 hedge funds and large institutions have $662K invested in Pasithea Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
25% more funds holding
Funds holding: 8 → 10 (+2)
0.03% less ownership
Funds ownership: 0.17% → 0.14% (-0.03%)
33% less capital invested
Capital invested by funds: $985K → $662K (-$323K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$21K |
| 4 |
VF
Virtu Financial
New York
|
+$15.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$95K |
| 2 |
MSFP
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
|
-$62K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$61.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$25K |
| 5 |
BlackRock
New York
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KPF
1
K2 Principal Fund
Toronto,
Ontario, Canada
| $497K | -$61.9K | -2,910 | -11% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $79K | +$22.9K | +1,078 | +38% |
|
|
3
State Street
Boston,
Massachusetts
| $24K | +$25.2K | +1,182 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $19K | +$21K | +986 | New |
|
|
VF
5
Virtu Financial
New York
| $15K | +$15.5K | +729 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $13K | +$13.6K | +640 | New |
|
|
SG
7
StoneX Group
New York
| $12.1K | +$12.8K | +600 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2K | +$2.4K | +113 | New |
|
9
JP Morgan Chase
New York
| $1K | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$95K | -3,647 | Closed |
|
|
MSFP
11
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
| – | -$62K | -2,400 | Closed |
|
|
TSS
12
Two Sigma Securities
New York
| – | -$25K | -945 | Closed |
|
|
13
BlackRock
New York
| – | -$13K | -498 | Closed |
|
14
Wells Fargo
San Francisco,
California
| – | +$21 | +1 | +25% |
|
KTTA Hedge Fund Activity: Q2 2022 in Review
10 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q2 2022, worth a combined $662K — down 33% from $985K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KTTA positions and 4 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $25.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $95K sold.
- 10 institutional investors held Pasithea Therapeutics (KTTA) as of Q2 2022, up from 8 in Q1 2022.
- Funds reported $662K of Pasithea Therapeutics stock for Q2 2022, down 33% quarter-over-quarter.
- 6 funds opened new Pasithea Therapeutics positions in Q2 2022 and 4 closed out, a net change of +2 holders.
- The largest Pasithea Therapeutics buyer in Q2 2022 was State Street, an estimated $25.2K added.
- The largest Pasithea Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $95K sold.
Based on aggregated 13F filings for Q2 2022.